Mabgeek Biotech has officially moved into WORLO COMPUTING-CHANGSHA INTELLIGENCE VALLEY

On March 27, the signing ceremony of Mabgeek Biotech's entry into the WORLO COMPUTING-CHANGSHA INTELLIGENCE VALLEY and the "AI+Biomedicine" innovation ecosystem exchange event were held, marking that Mabgeek Biotech, a leading domestic innovative drug research and development company, officially settled in the Lugu Industrial Park (Changsha Information Industry Park) (referred to as the "Park") in Changsha High-tech Zone.

On the morning of March 27, Mabgeek Biotech officially settled in the Lugu Industrial Park (Changsha Information Industrial Park) in Changsha High-tech Zone. Photo by Luo Zhongjie

As a leading company in the development of innovative drugs in China, Mabgeek Biotech has always focused on the discovery and commercialization of long-acting antibody drugs, and its core products have promoted a number of clinical studies.

As one of the ten key industrial chains in Xiangjiang New District, the biopharmaceutical and health industry chain has a total output value of over 86 billion yuan. As a core industrial zone, the park has gathered many listed companies such as Sinocare and Shengxiang Biotechnology. The entry of Mabgeek Biotech into the WORLO COMPUTING-CHANGSHA INTELLIGENCE VALLEY will inject new impetus into the integrated development of biopharmaceuticals and artificial intelligence in Changsha and even the central region.

"We believe that relying on the computing power advantage of WORLO COMPUTING-CHANGSHA INTELLIGENCE VALLEY will accelerate the realization of the beautiful vision of 'reshaping drug development with AI'." Xia Henian, deputy secretary of the Party Working Committee and director of the Management Committee of Lugu Industrial Park in Changsha High-tech Zone, said, "The entry of Mabgeek Biotech is an important breakthrough in the cross-border integration of 'AI+biomedicine' in the new zone. We will focus on the needs of enterprises, promote collaborative innovation between Mabgeek Biotech and local AI companies, universities and research institutes, jointly build an open ecosystem, achieve more hard-core scientific and technological achievements, and create a benchmark case of cross-border integration."

A roundtable forum on "AI drives the future: innovation and transformation of biomedicine" was also held on site. Representatives from Hunan Feique Medical Technology, Changsha Artificial Intelligence Innovation Center, Molecular Heart, Huishiwei and other companies conducted in-depth discussions and exchanges on the application of AI in drug design, gene analysis, clinical trial optimization and other scenarios, providing more new ideas and possibilities for the integrated development of "AI+biomedicine".

"Microsoft YaHei";">Original link: https://www.icswb.com/h/100046/20250327/918918_m.html